Logo

Roche Launches Ventana HER2 Dual ISH CDx for the Identification of Breast and Gastric Cancer

Share this

Roche Launches Ventana HER2 Dual ISH CDx for the Identification of Breast and Gastric Cancer

 Shots:

  • Roche’s Ventana HER2 Dual ISH DNA Probe Cocktail assay is used to detect HER2 biomarker in breast and gastric cancer patients receiving Herceptin (trastuzumab)
  • The approval of Ventana HER2 Dual ISH assay supports Roche’s personalized healthcare sector by providing techniques to diagnose breast and gastric cancer
  • The Ventana HER2 assay is fully automated on BenchMark IHC/ISH instruments providing results on the same day & can be read using light microscopy- launched in EU- the Middle East- Africa- Latin America & Asia Pacific with its expected regulatory submission to FDA 

Ref: Roche | Image:Roche

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions